Professor, Radiation Oncology, Washington University School of Medicine
Radiation Oncology
Dr. Perry W. Grigsby, MD
|
|
Give Review
Perry Grigsby is an expert in the field of Radiation Oncology. He graduated from University of Kentucky College of Medicine. University of Kentucky College of Medicine is ranked 63/72 in Research/PrimaryCare. He has 3 awards "America's Top Doctors", "America's Top Doctors for Cancer" and "CMS Meaningful Use Stage 1 Certification". Perry Grigsby has written publications. He has 101 publications published with PubMed. The lastest publication is: 'Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy.' Dr. Perry W. Grigsby is registered with Medicare.
Publications
- Intensity modulated radiation therapy for recurrent ovarian Cancer refractory to chemotherapy.
- Brachytherapy Is Associated With Improved Survival in Inoperable Stage I Endometrial Adenocarcinoma: A Population-Based Analysis.
- PET/MRI for the body imager: abdominal and pelvic oncologic applications.
- BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma.
- PET-Based Radiation Therapy Planning.
- Cervical Gross Tumor Volume Dose Predicts Local Control Using Magnetic Resonance Imaging/Diffusion-Weighted Imaging-Guided High-Dose-Rate and Positron Emission Tomogra...
- In Vitro Chemoresponse Analysis of Cervical Cancer Patient Specimens.
- Concomitant chemotherapy and radiation for the treatment of advanced-stage endometrial Cancer.
- Treatment Approach, Surveillance and Outcome of Well-differentiated Thyroid Cancer in Childhood and Adolescence.
- Curative Radiation Therapy for Locally Advanced Cervical Cancer: Brachytherapy Is NOT Optional.
- BRAF V600E mutational status in pediatric thyroid Cancer.
- Outcomes of Iodine-125 Plaque Brachytherapy for Uveal Melanoma With Intraoperative Ultrasonography and Supplemental Transpupillary Thermotherapy.
- The Effect of Small Tumor Volumes on Studies of Intratumoral Heterogeneity of Tracer Uptake.
- Response to the Letter to the Editor Regarding the Manuscript Entitled "Positron Emission Tomography with [(18)F]-3'-Deoxy-3'Fluorothymidine (FLT) as a Predictor of Ou...
- In vitro chemoresponse to cisplatin and outcomes in cervical Cancer.
- Positron Emission Tomography with [(18)F]-3'-Deoxy-3'fluorothymidine (FLT) as a Predictor of Outcome in Patients with Locally Advanced Resectable Rectal Cancer: a Pilo...
- Tumor volume and subvolume concordance between FDG-PET/CT and diffusion-weighted MRI for squamous cell carcinoma of the cervix.
- Improve definition of titanium tandems in MR-guided high dose rate brachytherapy for cervical Cancer using proton density weighted MRI.
- Changes in Cervical Cancer FDG Uptake During Chemoradiation and Association With Response.
- Temporal analysis of intratumoral metabolic heterogeneity characterized by textural features in cervical Cancer.
- Thyroid carcinoma uptake of 18F-fluorodeoxyglucose in patients with elevated serum thyroglobulin and negative 131I scintigraphy.
- Comparison of apparent diffusion coefficient maps to T2-weighted images for target delineation in cervix Cancer brachytherapy.
- Metabolic Response on Posttherapy FDG-PET Predicts Patterns of Failure After Radiotherapy for Cervical Cancer.
- ACR-ASTRO practice guideline for the performance of therapy with unsealed radiopharmaceutical sources.
- Magnitude of Interfractional Vaginal Cuff Movement: Implications for External Irradiation.
- Current Measures of Metabolic Heterogeneity within Cervical Cancer do not Predict Disease Outcome.
- Change in T2-Fat Saturation MRI Correlates with Outcome in Cervical Cancer Patients.
- The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy.
- Epithelial ovarian Cancer.
- Split-Field Helical Tomotherapy With or Without Chemotherapy for Definitive Treatment of Cervical Cancer.
- Management of cervical nodal metastasis detected on I-131 scintigraphy after initial surgery of well-differentiated thyroid carcinoma.
- Prospective Phase I-II Trial of Helical Tomotherapy with or Without Chemotherapy for Postoperative Cervical Cancer Patients.
- Prognostic Utility of Squamous Cell Carcinoma Antigen in Carcinoma of the Cervix: Association with Pre- and Posttreatment FDG-PET.
- Dosimetric effects of air pockets around high-dose rate brachytherapy vaginal cylinders.
- Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced...
- Lymph node staging by positron emission tomography in cervical Cancer: relationship to prognosis.
- Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical Cancer.
- A new method of anatomically conformal vaginal cuff HDR brachytherapy.
- A microRNA expression signature for cervical Cancer prognosis.
- 18F-fluorodeoxyglucose-positron emission tomography and pathologic tumor size in early-stage invasive cervical Cancer.
- Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience.
- Use of serial CT imaging for the quality assurance of MammoSite therapy.
- A miR-200 microRNA cluster as prognostic marker in advanced ovarian Cancer.
- Role of PET in gynecologic malignancy.
- Cervical Cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake.
- Effects of Cancer treatment on ovarian function.
- The role of 18F-FDG PET in assessing therapy response in Cancer of the cervix and ovaries.
- Sequential chemotherapy and irradiation in advanced stage endometrial Cancer: A Gynecologic Oncology Group phase I trial of doxorubicin-cisplatin followed by whole abd...
- Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical Cancer.
- 18-F-fluorodeoxyglucose-positron emission tomography evaluation of early metabolic response during radiation therapy for cervical Cancer.
- Prospective clinical trial of positron emission tomography/computed tomography image-guided intensity-modulated radiation therapy for cervical carcinoma with positive ...
- Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for ...
- Prognostic factors in patients with well-differentiated thyroid Cancer presenting with pulmonary metastasis.
- Intratumoral metabolic heterogeneity of cervical Cancer.
- Estimation of setup uncertainty using planar and MVCT imaging for gynecologic malignancies.
- An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in Cancer of the uterine cervix.
- Combined intensity-modulated radiation therapy and brachytherapy in the treatment of cervical Cancer.
- Notch-deficient skin induces a lethal systemic B-lymphoproliferative disorder by secreting TSLP, a sentinel for epidermal integrity.
- Tumor response and survival predicted by post-therapy FDG-PET/CT in anal Cancer.
- Assessing tumor hypoxia in cervical Cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).
- Are increased tumor aneuploidy and heightened cell proliferation along with heterogeneity associated with patient outcome for carcinomas of the uterine cervix? A combi...
- Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid Cancer.
- CD83 gene polymorphisms increase susceptibility to human invasive cervical Cancer.
- Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma.
- Effect of a T0 radical hysterectomy specimen on survival for early stage cervical Cancer.
- The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical Cancer treatment response and survival.
- The contribution of new imaging techniques in staging cervical Cancer.
- The role of FDG-PET/CT imaging after radiation therapy.
- Utility of parametrectomy for early stage cervical Cancer treated with radical hysterectomy.
- Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in Cancer of the uterine cervix.
- External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial Cancer.
- Anti-apoptotic peptides protect against radiation-induced cell death.
- Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial carcinoma.
- Adaptive brachytherapy treatment planning for cervical Cancer using FDG-PET.
- Lymph node metastases in differentiated thyroid Cancer under 2 cm.
- Contralateral papillary thyroid Cancer at completion thyroidectomy has no impact on recurrence or survival after radioiodine treatment.
- Bevacizumab combination therapy in heavily pretreated, recurrent cervical Cancer.
- Progress toward a microradiation therapy small animal conformal irradiator.
- FDG-PET/CT in the evaluation of anal carcinoma.
- FDG-PET imaging for the assessment of physiologic volume response during radiotherapy in cervix Cancer.
- F-18 fluorodeoxyglucose uptake in primary cervical Cancer as an indicator of prognosis after radiation therapy.
- Medicare coverage of PET for cervical Cancer.
- FDG-PET in carcinoma of the uterine cervix with endometrial extension.
- Sequential FDG-PET brachytherapy treatment planning in carcinoma of the cervix.
- Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography.
- 4th International Cervical Cancer Conference: update on PET and cervical Cancer.
- Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial Cancer.
- FDG-PET evaluation of vaginal carcinoma.
- Lack of benefit of concurrent chemotherapy in patients with cervical Cancer and negative lymph nodes by FDG-PET.
- Postoperative radiation therapy for grade II and III intracranial ependymoma.
- Cervix carcinoma, concurrent chemoradiotherapy, and salvage of isolated paraaortic lymph node recurrence.
- Cervical carcinoma in the elderly: an analysis of patterns of care and outcome.
- Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus Cancer.
- Lymph node control in cervical Cancer.
- Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome.
- A treatment planning study comparing HDR and AGIMRT for cervical Cancer.
- Preparation of patients with thyroid Cancer for 131I scintigraphy or therapy by 1-3 weeks of thyroxine discontinuation.
- Outcome analysis for stage IE and IIE thyroid lymphoma.
- Treatment planning guidelines regarding the use of CT/PET-guided IMRT for cervical carcinoma with positive paraaortic lymph nodes.
- Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical Cancer: an update of radiation therapy oncology group ...
Schools
University of Kentucky College of Medicine
Barnes Jewish Hospital S Campus
Conditions Treated
- Vulvar Cancer
Doctors Specialties
- Radiation Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
Education
-
Washington University - Barnes-Jewish Hospital -
University of Kentucky College of Medicine
Hospital
-
Barnes-Jewish Hospital -
St. Louis Children's Hospital
Drug Facts
| NPI NUMBER | 1467478685 | |
| NPPES Provider LastName | GRIGSBY | |
| NPPES Provider FirstName | PERRY | |
| NPPES Provider ZIPCode | 631101032 | |
| NPPES Provider State | MO | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 187.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1467478685 |
| Last Name Of The Provider | GRIGSBY |
| First Name Of The Provider | PERRY |
| View All |
Similar Doctors
|
|
Dr. Stephanie M. Perkins, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kathy L. Baglan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sahaja Acharya, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Benjamin W. Fischer-Valuck, MD |
|
|
Dr. Michael C. Roach, MD |